NCT04320290 is a Phase 4 clinical trial of Direct Acting Antivirals in Kidney Failure, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT04320290?

NCT04320290 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT04320290?

Interventions in NCT04320290: Direct Acting Antivirals.

What condition does NCT04320290 study?

NCT04320290 studies Kidney Failure, Hepatitis C.

Is NCT04320290 still recruiting?

NCT04320290 is currently withdrawn. Last updated 31 August 2022.

Last reviewed 2022-08-31 · How we verify

NCT04320290

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HCV + to HCV - Kidney Transplant

Withdrawn Phase 4 Last updated 31 August 2022

What this trial tests

Phase 4 trial testing Direct Acting Antivirals in Kidney Failure. Withdrawn.

Timeline

21 May 2020

Primary endpoint
16 June 2020

16 June 2020

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Start date	21 May 2020
Primary completion	16 June 2020
Estimated completion	16 June 2020

Drugs / interventions tested

Direct Acting Antivirals — full drug profile →

Conditions studied

Kidney Failure — all drugs for Kidney Failure →
Hepatitis C — all drugs for Hepatitis C →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Kidney Failure or Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center study characterizing the experience of administration of 8 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Direct Acting Antivirals

Trials testing the same drug.

NCT05372874 — Treatment of Hepatitis c by Using Direct-acting Antiviral · unknown
NCT05368974 — The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry · recruiting
NCT03894696 — Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents · unknown
NCT03702218 — Hepatitis C Positive Donor Into Hepatitis C Negative Recipients · EARLY_PHASE1 · withdrawn
NCT03481036 — DAA Therapy in Pediatric Patients With Chronic Hepatitis C · NA · unknown

Other recruiting trials for Kidney Failure

Currently open trials in the same condition.

NCT07492511 — Renal and Hepatic Abnormal Doppler Patterns in Trauma · recruiting
NCT06243731 — A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation · recruiting
NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
NCT06343727 — A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) · NA · recruiting
NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04320290 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 31 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04320290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing